Press release
Skin and Soft Tissue Infection Treatment Market - Quantifying Market Opportunities through Market Sizing and Market Forecasting
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an underlying cause such as diabetes or systemic immunosuppression.Get a Sample Brochure for this Report: http://bit.ly/2aRNfDL
Skin and soft tissue infections (SSTIs) may be caused by any of the pathogenic microorganisms which include Staphylococcus aureus, Streptococcus pyogene, gram-negative bacilli, Pseudomonas aeruginosa, beta-hemolytic streptococci, Enterococcus, streptococci, staphylococci, Peptostreptococcus, Bacteroides, Clostridium and S. pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) and streptococci are the most common organisms causing skin and soft tissue infections (SSTIs).
The rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections has resulted in the need for new therapies to combat the serious skin and soft tissue infections. In addition, new product developments will drive the skin and soft tissue infections treatment market. Recently, in February 2014, Cubist Pharmaceuticals, Inc. announced that its Marketing Authorization Application (MAA) for investigational candidate tedizolid phosphate has been accepted by the European Medicines Agency (EMA) for review. With a decision expected from the European Commission (EC) during the first half of 2015, the company seeks to market its new product for the treatment of skin and soft tissue infections.
Prior to EMA, the U.S. FDA accepted company’s New Drug Application (NDA) for review and the company had also planned for submitting a New Drug Submission (NDS) in Canada in 2014 for tedizolid intended for the treatment of skin and soft tissue infections. Moreover, in December 2013, Durata Therapeutics, Inc. announced the acceptance of its Marketing Authorization Application (MAA) for dalbavancin, intended for the treatment of skin and soft tissue infections, by the European Medicines Agency (EMA) for review.
Research Report: http://www.transparencymarketresearch.com/skin-soft-tissue-infection-treatment-market.html
The Infectious Diseases Society of America has recently released guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs). This practice guideline is to guide the physicians in proper diagnosis and efficient treatment of the skin and soft tissue infections and avoid serious consequences. Based on geography, the skin and soft tissue infections treatment market is analyzed into North America, Europe, Asia-Pacific and Rest of the World.
Some of the companies engaged in the development of skin and soft tissue infection (SSTI) treatment medications include Cubist Pharmaceuticals, Inc., Wockhardt Limited, Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and Melinta Therapeutics Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Skin and Soft Tissue Infection Treatment Market - Quantifying Market Opportunities through Market Sizing and Market Forecasting here
News-ID: 353681 • Views: …
More Releases from TMR GROUP
Virtual Microscopy Market to be Driven by Rising Prevalence of Cancer
Virtual microscopy may be defined as the process of placing microscopic images on computer networks that can be viewed by a large number of people across different locations. Virtual microscopy is based on the computer-based technology that combines microscopy technologies and digital technologies, both. Virtual microscopy allows the viewing of virtual slide with speed and ease. Virtual microscopy is widely being used across clinical and diagnostic laboratories, drug discovery and…
Silver Sulfadiazine Market - Pin Point Analysis of Changing Competition Dynamics
Silver sulfadiazine is an antibacterial drug used for making personal care products such as anti-burn creams. Silver sulfadiazine is listed in the World Health Organization’s List of Essential Medicines and is widely used as an antibiotic for treating second and third degree burns on the skin. Silver sulfadiazine prevents the growth of bacteria and yeast on the skin. This drug is also commonly used to treat urinary tract infections (UTIs).…
Medical Traction Devices Market Driven by Increasing Adoption in the U.S. and Ca …
Medical traction is a therapeutic method used in treating several situations such as muscle contracture, bone fractures, bone deformities (e.g. scoliosis, kyphosis and lordosis) and long-duration muscle spasms. Traction is widely used procedure for low back pain (LBP) and is prescribed in conjunction with other therapies and treatments. Although the results obtained from adoption of traction have been encouraging, there is insufficient clinical data to support the usage of traction…
Global Laboratory Information System Market Propelled by Growing Demand for Impr …
A laboratory information system is a software-based laboratory and information management system that stores and manages information from every stage of medical tests and procedures. The demand for laboratory management systems has been rising rapidly across the world. The increased need for the improvement in laboratory competence and escalating demand for integrated healthcare information systems are driving the global laboratory information systems market significantly.
According to this research study, the worldwide…
More Releases for SSTI
Skin and Soft Tissue Infections Market Trends, Growth Drivers & Forecast 2024-20 …
The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.
The Skin and Soft Tissue Infections Market Report by DataM Intelligence offers comprehensive insights into the latest market trends, key growth drivers, and emerging challenges. Crafted to support smarter and faster decision-making, our reports blend in-depth…
Comprehensive Growth Forecast for Skin and Soft Tissue Infection Treatment Marke …
Skin and Soft Tissue Infection Treatment Market Insights: Trends, Drivers, and Outlook 2024 - 2031
Skin and Soft Tissue Infection Treatment Market Scope: Unveiling Today's Trends
Skin and Soft Tissue Infection Treatment involves therapies and medications aimed at addressing infections affecting the skin and underlying tissues. The market for these treatments has been experiencing significant growth, driven by rising incidences of surgical site infections, increasing awareness of antibiotic resistance, and the ongoing…
Insights on the Linezolid Market to 2027 | Industry Statistics, Emerging Demands …
The global Linezolid market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Linezolid is an antibiotic drug that is used for the treatment of serious bacterial infections such as gram-positive bacteria, pneumonia, skin infections, and infections that are resistant to other antibiotics by stopping the growth of bacteria. This drug is either consumed by mouth or by injecting directly into the vein. The major factor…
Linezolid Drug Market Size, Key Trends, Challenges and Standardization, Research …
Complete study of the global Linezolid Drug market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Linezolid Drug industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also…
Skin and Soft Tissue Infection Treatment Market: Evolving Technology, Trends and …
Skin and Soft Tissue Infection Treatment Market: Overview
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an…
New Product Developments will Drive the Skin and Soft Tissue Infection Treatment …
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an underlying cause such as diabetes or systemic immunosuppression.
Skin…
